Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Demethylating agents in myeloid malignancies

7 Oct 2008

Abstract excerpt

PURPOSE OF REVIEW: Two demethylating agents are approved in myelodysplastic syndromes (MDS): 5-azacitidine and 5-aza-2'-deoxycitidine (decitabine). These drugs are structurally related and induce DNA hypomethylation. Aberrant DNA methylation is associated with gene silencing. It is proposed that hypomethylating agents work by inducing reexpression of epigenetically silenced genes. Here, we provide an up-to-date...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18841054
DOI: 10.1097/cco.0b013e328313699c

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Demethylating agents in myeloid malignanciesPMID 18841054Read ↗

Demethylating Agents in the Treatment of CancerSemantic proximity Read ↗

Clinical development of demethylating agents in hematologySemantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

The use of hypomethylating agents in the treatment of hematologic malignanciesSemantic proximity Read ↗

[Hypomethylating agents for the treatment of myelodysplastic syndromes].Semantic proximity Read ↗

Decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabineSemantic proximity Read ↗

Clinical Results of Hypomethylating Agents in AML TreatmentSemantic proximity Read ↗

DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AMLSemantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.